Iron-catalyzed oxidative synthesis of N-heterocycles from primary alcohols

Dan Zhao, Yu-Ren Zhou, Qi Shen and Jian-Xin Li*
State Key lab of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210093, P. R. China. E-mail: lijxnju@nju.edu.cn; Fax: +86-25-83686419; Tel: +86-25-83686419

Received 3rd November 2013 , Accepted 24th December 2013

First published on 3rd January 2014


Abstract

An iron-catalyzed one-pot one-step oxidative system has been successfully developed in the conversion of primary alcohols into nitrogen-containing heterocycles, such as quinazolinone, quinazoline and 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide derivatives.


Quinazolinone as a building block occurs widely in natural products that exhibit a broad range of useful biological and pharmacological activities.1 It is assigned as a privileged skeleton in drug discovery and many synthetic efforts have been made for its construction.2 Transition metals have been extensively utilized in the syntheses of quinazolinones, for example ruthenium and platinum complexes were involved in their preparations via reductive N-heterocyclization.3 Multicomponent reactions catalyzed by transition metals, such as gallium(III) triflate4a or cerium(IV) ammonium nitrate,4b were also described. Since 2000, Alper and co-authors have reported methods via tandem reactions, in which palladium-catalyzed cyclocarbonylation of 2-iodoanilines or their derivatives was the key step.5 Later, Zhu group developed a palladium-catalyzed intramolecular C(sp2)–H carboxamidation of N-arylamidines, providing a more efficient approach to quinazolinones.6 Recently, copper or iron-catalyzed C–N couplings have made great achievements, and were applied in synthesis of quinazolinones using 2-halobenzoic acid derivatives and ammonia sources as starting materials.7 However, stoichiometric amounts of bases were essential for the reactions, and in some cases ligands were also necessary.

As shown in Scheme 1, one of the typical synthetic methods is to utilize a condensation reaction between aldehyde and o-aminobenzamide 2 followed by oxidation of the aminal intermediate. For this oxidation, stoichiometric or large excess amounts of toxic oxidants, such as KMnO4,8a MnO2,8b DDQ,8c CuCl2,8d were required. Some molecules that can be oxidized to aldehydes might be also used as starting materials. Very recently, Wu converted aromatic ketones into corresponding aldehydes via Kornblum oxidation, and used these to react with o-aminobenzamide for synthesis of quinazolinones.9 Because many strategies have been devised for oxidation of alcohols to carbonyl compounds, obviously, alcohols could be substrates in this transformation. In 2011, Zhou described an oxidative cyclization of primary alcohols with o-aminobenzamides to quinazolinones catalyzed by iridium complex under hydrogen transfer conditions.10a Later, ruthenium-catalyzed hydrogen transfer was also applied (Scheme 1, method A).10b Thinking about high temperature and long reaction time in method A, an oxidation protocol, which involved inexpensive and less toxic catalysts with green oxidants was an alternative choice. Very recently, Wei group reported I2-catalyzed two-step oxidative system for synthesis of quinazolinones using DMSO as a mild oxidant (Scheme 1, method B).11 Due to the importance of quinazolinone skeleton, development of simple and environmentally benign protocols using convenient catalysts is still highly desired. Considering iron complexes as inexpensive and nontoxic catalysts were used for the oxidation of alcohols to the corresponding carbonyl compounds in the presence of peroxide,12 we hypothesize that, in an iron-catalyzed domino sequence as shown in Scheme 1, oxidation of alcohol 1 to aldehyde followed by condensation with o-aminobenzamide 2 might provide quinazolinone 3 via the oxidation of the generated aminal intermediate. This synthetic route is a one-pot one-step oxidative system, and has an additional advantage of operational convenience.


image file: c3ra46363j-s1.tif
Scheme 1 Synthesis of quinazolinones from primary alcohols.

Results and discussion

To exam our hypothesis, we chose benzyl alcohol 1a and o-aminobenzamide 2 as model substrates (Table 1). Initially, FeCl3 (5 mol%) with TBHP (5.5 M in decane) was investigated for detecting availability of the catalytic system. Fortunately, the reaction gave the target product, 2-phenylquinazolin-4(3H)-one 3a in DMSO (entry 1). Some abundant and cheap catalysts were also tested, while, the data indicated that FeCl3 was the most effective one, giving the product in a moderate yield at 60 °C for 12 h (entries 1–4). Among all the solvents screened, such as DMSO, toluene, DMF, 1,4-dioxane, acetonitrile and water, DMSO was the best one (entries 1, 5–9). It should be noted that although several loadings of FeCl3 were tested, 2 mol% gave a better result (entry 10), probably due to significant unknown byproduct formation with a relatively high catalyst loading. After screening the effect of reaction temperature and time (entries 11–18), the appropriate yield was achieved with the reaction conditions of 1a and 2 at 60 °C for 7 h. Increasing or decreasing the amount of TBHP did not improve the yield significantly (entries 19 and 20). In addition, when T-HYDRO was used as an oxidant, a lower yield was obtained (entry 21). After examining the reaction profiles, we decided the conditions of entry 16 as the optimal one for our next investigations of the substrate scope.
Table 1 Optimization of reaction conditionsa

image file: c3ra46363j-u1.tif

Entry Cat. (mol%) Solvent Temp. (°C) Time (h) Yieldb (%)
a Reaction conditions: 1a (1.5 mmol), 2 (0.5 mmol), solvent (2 mL), 5.5 M TBHP in decane (1.5 mmol), sealed tube, under an air atmosphere.b Isolated yield.c TBHP (2 mmol).d TBHP (1 mmol).e T-HYDRO = 70% TBHP in water (1.5 mmol).
1 FeCl3 (5) DMSO 60 12 51∼
2 CuCl2 (5) DMSO 60 12 24
3 ZnCl2 (5) DMSO 60 12 26
4 NiCl2 (5) DMSO 60 12 42
5 FeCl3 (5) Toluene 60 12 40
6 FeCl3 (5) DMF 60 12 Trace
7 FeCl3 (5) 1,4-Dioxane 60 12 Trace
8 FeCl3 (5) CH3CN 60 12 46
9 FeCl3 (5) H2O 60 12 44
10 FeCl3 (2) DMSO 60 12 93
11 FeCl3 (2) DMSO 70 12 86
12 FeCl3 (2) DMSO 50 12 90
13 FeCl3 (2) DMSO 80 12 84
14 FeCl3 (2) DMSO 40 12 86
15 FeCl3 (2) DMSO 60 10 92
16 FeCl3 (2) DMSO 60 7 93
17 FeCl3 (2) DMSO 60 5 85
18 FeCl3 (2) DMSO 60 3 75
19c FeCl3 (2) DMSO 60 7 91
20d FeCl3 (2) DMSO 60 7 81
21e FeCl3 (2) DMSO 60 7 73


With the optimized conditions in hand, various primary alcohols were investigated (Table 2). For different substituted benzyl alcohols with electron donating and withdrawing groups gave moderate to good yields. Notably, C–X (F, Cl, Br and I) bond remained intact during the reaction (entries 5–8), which provided an additional handle for further elaboration of products. Heteroaryl substrate like 2-furylmethanol was examined and the corresponding product 3i was obtained in 76% yield (entry 9). In order to demonstrate the broad synthetic utility of this system, we investigated more challenging alkyl primary alcohols such as ethanol and octanol, fortunately, the desired products were also afforded with moderate yields (entries 10 and 11). However, 1-naphthalenemethanol produced an inseparable mixture of products (entry 12).

Table 2 Synthesis of quinazolin-4(3H)-ones catalyzed by FeCl3a

image file: c3ra46363j-u2.tif

Entry R Product Yieldb (%)
a Reaction conditions: 1 (1.5 mmol), 2 (0.5 mmol), FeCl3 (2 mol%), 5.5 M TBHP in decane (1.5 mmol), DMSO (2 mL), sealed tube, under an air atmosphere, at 60 °C for 7 h.b Isolated yield.c Not detected.
1 Ph 3a 93
2 2-Me-C6H4 3b 57
3 4-Me-C6H4 3c 66
4 4-MeO-C6H4 3d 37
5 4-F-C6H4 3e 40
6 4-Cl-C6H4 3f 45
7 2-Br-C6H4 3g 84
8 2-I-C6H4 3h 67
9 2-furyl 3i 76
10 Me 3j 42
11 Heptyl 3k 60
12 1-Naphthyl 3l Ndc


The success of above results encouraged us to further extend the substrate scope beyond o-aminobenzamide. Because of the structural similarity, we explored the possibility of using o-aminobenzylamine as starting material for synthesis of quinazolines which exhibit important biological properties.13 Substituted quinazolines have been synthesized by a variety of methods,14 one strategy is through the oxidative condensation of o-aminobenzylamine with aldehydes mediated by strong oxidants such as DDQ,15a MnO2 (ref. 15b) and NaClO.15c Later, Cu/N-ligand/TEMPO16a and bi-metallic alloyed nanoclusters/dimeric catechol catalytic systems16b were developed as more environmentally benign methods. Very recently, an Ir-catalyzed hydrogen transfer reaction was also applied in the synthesis of substituted quinazolines starting from o-aminobenzylamine and aldehydes.17 Encouraged by above results, we tested the employment of primary alcohols instead of aldehydes, the current synthetic strategy still worked well and the results were listed in Table 3. As benzyl alcohols (entries 1–7), heteroaryl primary alcohols (entries 8 and 9) and alkyl primary alcohol (entry 10) were employed, the corresponding products were obtained in moderate yields.

Table 3 Synthesis of quinazolines catalyzed by FeCl3a

image file: c3ra46363j-u3.tif

Entry R Product Yieldb (%)
a Reaction conditions: 1 (1.5 mmol), 4 (0.5 mmol), FeCl3 (2 mol%), 5.5 M TBHP in decane (1.5 mmol), DMSO (2 mL), sealed tube, under N2 atmosphere, at 60 °C for 6 h.b Isolated yield.
1 Ph 5a 70
2 2-Me-C6H4 5b 60
3 4-Me-C6H4 5c 71
4 4-MeO-C6H4 5d 71
5 4-F-C6H4 5e 55
6 4-Cl-C6H4 5f 62
7 1-Naphthyl 5g 65
8 3-Pyridyl 5h 35
9 2-Furyl 5i 44
10 Me 5j 53


Having successfully achieved the synthesis of quinazolinones and quinazolines, we tried to expand the current catalytic system to the synthesis of 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide derivatives. Benzothiadiazine derivatives, such as cyclothiazide and 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (IDRA-21) were the modulators of AMPA receptor desensitization.18 Very recently, a Pd-catalyzed synthetic route was developed for the preparation of benzothiadiazine derivatives by using o-aminobenzene-sulfonamide and primary alcohols as starting materials.19 Generally, these compounds were prepared from o-amino-benzenesulfonamide by condensation with aldehydes or ethyl hemiacetals in acidic medium.20 As shown in Table 4, using the present system, the final products, cyclic aminals (7) without C[double bond, length as m-dash]N bond formation were obtained. The result indicated the second oxidation didn't occur in current conditions. Both aryl and alkyl primary alcohols were tolerated in this transformation, and aryl primary alcohols were more reactive.

Table 4 Synthesis of 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides catalyzed by FeCl3a

image file: c3ra46363j-u4.tif

Entry R Product Yieldb (%)
a Reaction conditions: 1 (1.5 mmol), 6 (0.5 mmol), FeCl3 (2 mol%), 5.5 M TBHP in decane (1.5 mmol), DMSO (2 mL), sealed tube, under an air atmosphere, at 60 °C for 12 h.b Isolated yield.
1 Ph 7a 75
2 2-Me-C6H4 7b 57
3 4-Me-C6H4 7c 83
4 4-MeO-C6H4 7d 58
5 4-F-C6H4 7e 39
6 4-Cl-C6H4 7f 47
7 2-Br-C6H4 7g 51
8 2-I-C6H4 7h 52
9 1-Naphthyl 7i 44
10 Me 7j 24
11 Heptyl 7k 29


Conclusions

In summary, we have successfully developed an iron-catalyzed one-pot one-step oxidative system for the synthesis of N-heterocycles from the cyclization of primary alcohols 1 with o-aminobenzamide 2, o-aminobenzylamine 4 or o-aminobenzenesulfonamide 6 using similar conditions. Furthermore, this environmentally friendly protocol displays good functional group compatibility and both aromatic and alkyl primary alcohols were reactive. The present results provided an economic and feasible way to prepare bioavailable skeletons, such as quinazolinones, quinazolines and benzothiadiazine derivatives.

Acknowledgements

This work was supported by National Natural Science Foundation of China (21272114, 90913023), and the National Natural Science Fund for Creative Research Groups (21121091).

Notes and references

  1. (a) S. B. Mhaske and N. P. Argade, Tetrahedron, 2006, 62, 9787–9826 CrossRef CAS PubMed and references therein; (b) A. Witt and J. Bergman, Curr. Org. Chem., 2003, 7, 659–677 CrossRef CAS and references therein.
  2. For selected examples, see: (a) D. A. Horton, G. T. Bourne and M. L. Smythe, Chem. Rev., 2003, 103, 893–930 CrossRef CAS PubMed; (b) D. J. Connolly, D. Cusack, T. P. O'Sullivan and P. J. Guiry, Tetrahedron, 2005, 61, 10153–10202 CrossRef CAS PubMed; (c) A. Kamal, K. S. Reddy, B. R. Prasad, A. H. Babu and A. V. Ramana, Tetrahedron Lett., 2004, 45, 6517–6521 CrossRef CAS PubMed; (d) J. F. Liu, P. Ye, B. L. Zhang, G. Bi, K. Sargent, L. B. Yu, D. Yohannes and C. M. Baldino, J. Org. Chem., 2005, 70, 6339–6345 CrossRef CAS PubMed; (e) J. F. Liu, P. Ye, K. Sprague, K. Sargent, D. Yohannes, C. M. Baldino, C. J. Wilson and S. C. Ng, Org. Lett., 2005, 7, 3363–3366 CrossRef CAS PubMed; (f) A. H. Romero, J. Salazar and S. E. Lopez, Synthesis, 2013, 45, 2043–2050 CrossRef CAS PubMed; (g) H. Hikawa, Y. Ino, H. Suzuki and Y. Yokoyama, J. Org. Chem., 2012, 77, 7046–7051 CrossRef CAS PubMed; (h) H. Wang, X. Cao, F. Xiao, S. Liu and G.-J. Deng, Org. Lett., 2013, 15, 4900–4903 CrossRef CAS PubMed.
  3. M. Akazome, T. Kondo and Y. Watanabe, J. Org. Chem., 1993, 58, 310–312 CrossRef CAS.
  4. (a) J. Chen, D. Wu, F. He, M. Liu, H. Wu, J. Ding and W. Su, Tetrahedron Lett., 2008, 49, 3814–3818 CrossRef CAS PubMed; (b) D. Rocchi, J. Francisco Gonzalez and J. Carlos Menendez, Green Chem., 2013, 15, 511–517 RSC.
  5. (a) C. Larksarp and H. Alper, J. Org. Chem., 2000, 65, 2773–2777 CrossRef CAS; (b) Z. Zheng and H. Alper, Org. Lett., 2008, 10, 829–832 CrossRef CAS PubMed; (c) F. Zeng and H. Alper, Org. Lett., 2010, 12, 1188–1191 CrossRef CAS PubMed; (d) F. Zeng and H. Alper, Org. Lett., 2010, 12, 3642–3644 CrossRef CAS PubMed.
  6. B. Ma, Y. Wang, J. Peng and Q. Zhu, J. Org. Chem., 2011, 76, 6362–6366 CrossRef CAS PubMed.
  7. (a) H. Xu and H. Fu, Chem. – Eur. J., 2012, 18, 1180–1186 CrossRef CAS PubMed; (b) X. Liu, H. Fu, Y. Jiang and Y. Zhao, Angew. Chem., Int. Ed., 2009, 48, 348–351 CrossRef CAS PubMed; (c) J. Zhou, L. Fu, M. Lv, J. Liu, D. Pei and K. Ding, Synthesis, 2008, 3974–3980 CAS; (d) D. K. Sreenivas, N. Ramkumar and R. Nagarajan, Org. Biomol. Chem., 2012, 10, 3417–3423 RSC; (e) W. Xu, Y. Jin, H. Liu, Y. Jiang and H. Fu, Org. Lett., 2011, 13, 1274–1277 CrossRef CAS PubMed; (f) W. Xu and H. Fu, J. Org. Chem., 2011, 76, 3846–3852 CrossRef CAS PubMed; (g) X. Zhang, D. Ye, H. Sun, D. Guo, J. Wang, H. Huang, X. Zhang, H. Jiang and H. Liu, Green Chem., 2009, 11, 1881–1888 RSC; (h) X. Huang, H. Yang, H. Fu, R. Qiao and Y. Zhao, Synthesis, 2009, 2679–2688 CAS.
  8. (a) T. Hisano, M. Ichikawa, A. Nakagawa and M. Tsuji, Chem. Pharm. Bull., 1975, 23, 1910–1916 CrossRef CAS; (b) C. Balakumar, P. Lamba, D. P. Kishore, B. L. Narayana, K. V. Rao, K. Rajwinder, A. R. Rao, B. Shireesha and B. Narsaiah, Eur. J. Med. Chem., 2010, 45, 4904–4913 CrossRef CAS PubMed; (c) Y. Mitobe, S. Ito, T. Mizutani, T. Nagase, N. Sato and S. Tokita, Bioorg. Med. Chem. Lett., 2009, 19, 4075–4078 CrossRef CAS PubMed; (d) R. J. Abdel-Jalil, W. Voelter and M. Saeed, Tetrahedron Lett., 2004, 45, 3475–3476 CrossRef CAS PubMed.
  9. Y.-P. Zhu, Z. Fei, M.-C. Liu, F.-C. Jia and A.-X. Wu, Org. Lett., 2013, 15, 378–381 CrossRef CAS PubMed.
  10. (a) J. Zhou and J. Fang, J. Org. Chem., 2011, 76, 7730–7736 CrossRef CAS PubMed; (b) A. J. A. Watson, A. C. Maxwell and J. M. J. Williams, Org. Biomol. Chem., 2012, 10, 240–243 RSC.
  11. W. Ge, X. Zhu and Y. Wei, RSC Adv., 2013, 3, 10817–10822 RSC.
  12. For selected examples, see: (a) S. E. Martin and A. Garrone, Tetrahedron Lett., 2003, 44, 549–552 CrossRef CAS; (b) A. Al-Hunaiti, T. Niemi, A. Sibaouih, P. Pihko, M. Leskela and T. Repo, Chem. Commun., 2010, 46, 9250–9252 RSC; (c) F. Shi, M. K. Tse, M.-M. Pohl, A. Brueckner, S. Zhang and M. Beller, Angew. Chem., Int. Ed., 2007, 46, 8866–8868 CrossRef CAS PubMed; (d) F. Shi, M. K. Tse, Z. Li and M. Beller, Chem. – Eur. J., 2008, 14, 8793–8797 CrossRef CAS PubMed; (e) B. Join, K. Moeller, C. annenberg, K. Ziebart, K. Schroeder, D. Goerdes, K. Thurow, A. SpJunge and M. Beller, Adv. Synth. Catal., 2011, 353, 3023–3030 CrossRef CAS; (f) N. Panda and A. K. Jena, J. Org. Chem., 2012, 77, 9401–9406 CrossRef CAS PubMed.
  13. (a) H. A. Burris, Oncologist, 2004, 9, 10–15 CrossRef CAS PubMed; (b) B. A. Foster, H. A. Coffey, M. J. Morin and F. Rastinejad, Science, 1999, 286, 2507–2510 CrossRef CAS; (c) C. Girard, S. Liu, F. Cadepond, D. Adams, C. Lacroix, M. Verleye, J. M. Gillardin, E. E. Baulieu, M. Schumacher and G. Schweizer-Groyer, Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 20505–20510 CrossRef CAS PubMed; (d) S. J. Hays, B. W. Caprathe, J. L. Gilmore, N. Amin, M. R. Emmerling, W. Michael, R. Nadimpalli, R. Nath, K. J. Raser, D. Stafford, D. Watson, K. Wang and J. C. Jaen, J. Med. Chem., 1998, 41, 1060–1067 CrossRef CAS PubMed; (e) A. Luth and W. Lowe, Eur. J. Med. Chem., 2008, 43, 1478–1488 CrossRef PubMed; (f) R. Gundla, R. Kazemi, R. Sanam, R. Muttineni, J. Sarma, R. Dayam and N. Neamati, J. Med. Chem., 2008, 51, 3367–3377 CrossRef CAS PubMed; (g) J. F. M. da Silva, M. Walters, S. Al-Damluji and C. R. Ganellin, Bioorg. Med. Chem., 2008, 16, 7254–7263 CrossRef PubMed; (h) L. A. Doyle and D. D. Ross, Oncogene, 2003, 22, 7340–7358 CrossRef PubMed.
  14. For recent examples, see: (a) X. Su, C. Chen, Y. Wang, J. Chen, Z. Lou and M. Li, Chem. Commun., 2013, 49, 6752–6754 RSC; (b) J. Zhang, C. Yu, S. Wang, C. Wan and Z. Wang, Chem. Commun., 2010, 46, 5244–5246 RSC; (c) B. Han, C. Wang, R.-F. Han, W. Yu, X.-Y. Duan, R. Fang and X.-L. Yang, Chem. Commun., 2011, 47, 7818–7820 RSC; (d) S. K. Panja, N. Dwivedi and S. Saha, Tetrahedron Lett., 2012, 53, 6167–6172 CrossRef CAS PubMed; (e) Y. Yan, Y. Zhang, C. Feng, Z. Zha and Z. Wang, Angew. Chem., Int. Ed., 2012, 51, 8077–8081 CrossRef CAS PubMed; (f) R. Sarma and D. Prajapati, Green Chem., 2011, 13, 718–722 RSC; (g) Y. Yan and Z. Wang, Chem. Commun., 2011, 47, 9513–9515 RSC; (h) C. Huang, Y. Fu, H. Fu, Y. Jiang and Y. Zhao, Chem. Commun., 2008, 6333–6335 RSC; (i) Y. Lv, Y. Li, T. Xiong, W. Pu, H. Zhang, K. Sun, Q. Liu and Q. Zhang, Chem. Commun., 2013, 49, 6439–6441 RSC; (j) Z.-H. Zhang, X.-N. Zhang, L.-P. Mo, Y.-X. Li and F.-P. Ma, Green Chem., 2012, 14, 1502–1506 RSC; (k) M. A. McGowan, C. Z. McAvoy and S. L. Buchwald, Org. Lett., 2012, 14, 3800–3803 CrossRef CAS PubMed; (l) P. Sang, Y. Xie, J. Zou and Y. Zhang, Org. Lett., 2012, 14, 3894–3897 CrossRef CAS PubMed; (m) Y. Wang, H. Wang, J. Peng and Q. Zhu, Org. Lett., 2011, 13, 4604–4607 CrossRef CAS PubMed; (n) J. Zhang, D. Zhu, C. Yu, C. Wan and Z. Wang, Org. Lett., 2010, 12, 2841–2843 CrossRef CAS PubMed.
  15. (a) J. J. Vandeneynde, J. Godin, A. Mayence, A. Maquestiau and E. Anders, Synthesis, 1993, 867–869 CrossRef CAS PubMed; (b) Y. Y. Peng, Y. Y. Zeng, G. Y. S. Qiu, L. S. Cai and V. W. Pike, J. Heterocycl. Chem., 2010, 47, 1240–1245 CrossRef CAS; (c) C. U. Maheswari, G. S. Kumar, M. Venkateshwar, R. A. Kumar, M. L. Kantam and K. R. Reddy, Adv. Synth. Catal., 2010, 352, 341–346 CrossRef CAS.
  16. (a) B. Han, X. L. Yang, C. Wang, Y. W. Bai, T. C. Pan, X. Chen and W. Yu, J. Org. Chem., 2012, 77, 1136–1142 CrossRef CAS PubMed; (b) H. Yuan, W.-J. Yoo, H. Miyamura and S. Kobayashi, Adv. Synth. Catal., 2012, 354, 2899–2904 CrossRef CAS.
  17. J. Fang, J. Zhou and Z. Fang, RSC Adv., 2013, 3, 334–336 RSC.
  18. (a) F. Impagnatiello, A. Oberto, P. Longone, E. Costa and A. Guidotti, Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 7053–7058 CrossRef CAS; (b) D. M. Thompson, A. Guidotti, M. Dibella and E. Costa, Proc. Natl. Acad. Sci. U. S. A., 1995, 92, 7667–7671 CrossRef CAS; (c) N. Nagarajan, C. Quast, A. R. Boxall, M. Shahid and C. Rosenmund, Neuropharmacology, 2001, 41, 650–663 CrossRef CAS; (d) I. Zivkovic, D. M. Thompson, M. Bertolino, D. Uzunov, M. Dibella, E. Costa and A. Guidotti, J. Pharmacol. Exp. Ther., 1995, 272, 300–309 CAS.
  19. H. Hikawa, N. Matsuda, H. Suzuki, Y. Yokoyama and I. Azumaya, Adv. Synth. Catal., 2013, 355, 2308–2320 CrossRef CAS.
  20. (a) P. de Tullio, S. Boverie, B. Becker, M. H. Antoine, Q. A. Nguyen, P. Francotte, S. Counerotte, S. Sebille, B. Pirotte and P. Lebrun, J. Med. Chem., 2005, 48, 4990–5000 CrossRef CAS PubMed; (b) S. Boverie, M. H. Antoine, F. Somers, B. Becker, S. Sebille, R. Ouedraogo, S. Counerotte, B. Pirotte, P. Lebrun and P. de Tullio, J. Med. Chem., 2005, 48, 3492–3503 CrossRef CAS PubMed; (c) D. Braghiroli, G. Puia, G. Cannazza, A. Tait, C. Parenti, G. Losi and M. Baraldi, J. Med. Chem., 2002, 45, 2355–2357 CrossRef CAS PubMed; (d) J. M. Loynes, H. F. Ridley and R. G. Spickett, J. Med. Chem., 1965, 8, 691–694 CrossRef CAS.

Footnote

Electronic supplementary information (ESI) available: Experimental section, spectral data and other information. See DOI: 10.1039/c3ra46363j

This journal is © The Royal Society of Chemistry 2014
Click here to see how this site uses Cookies. View our privacy policy here.